WO2003045360A3 - Use of gaba for the treatment of intestinal inflammations - Google Patents

Use of gaba for the treatment of intestinal inflammations Download PDF

Info

Publication number
WO2003045360A3
WO2003045360A3 PCT/EP2002/012001 EP0212001W WO03045360A3 WO 2003045360 A3 WO2003045360 A3 WO 2003045360A3 EP 0212001 W EP0212001 W EP 0212001W WO 03045360 A3 WO03045360 A3 WO 03045360A3
Authority
WO
WIPO (PCT)
Prior art keywords
gaba
treatment
intestinal inflammations
inflammations
intestinal
Prior art date
Application number
PCT/EP2002/012001
Other languages
German (de)
French (fr)
Other versions
WO2003045360A2 (en
Inventor
Markus B Kalousek
Hans-Dieter Grimmecke
Frank Seibold
Original Assignee
Laves Arzneimittel Gmbh
Markus B Kalousek
Hans-Dieter Grimmecke
Frank Seibold
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laves Arzneimittel Gmbh, Markus B Kalousek, Hans-Dieter Grimmecke, Frank Seibold filed Critical Laves Arzneimittel Gmbh
Priority to AU2002350640A priority Critical patent/AU2002350640A1/en
Publication of WO2003045360A2 publication Critical patent/WO2003045360A2/en
Publication of WO2003045360A3 publication Critical patent/WO2003045360A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of GABA for treating intestinal inflammations which are not mediated by T cells.
PCT/EP2002/012001 2001-11-29 2002-10-28 Use of gaba for the treatment of intestinal inflammations WO2003045360A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002350640A AU2002350640A1 (en) 2001-11-29 2002-10-28 Use of gaba for the treatment of intestinal inflammations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10158601A DE10158601A1 (en) 2001-11-29 2001-11-29 Use of GABA to treat intestinal inflammation
DE10158601.9 2001-11-29

Publications (2)

Publication Number Publication Date
WO2003045360A2 WO2003045360A2 (en) 2003-06-05
WO2003045360A3 true WO2003045360A3 (en) 2003-09-18

Family

ID=7707398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/012001 WO2003045360A2 (en) 2001-11-29 2002-10-28 Use of gaba for the treatment of intestinal inflammations

Country Status (3)

Country Link
AU (1) AU2002350640A1 (en)
DE (1) DE10158601A1 (en)
WO (1) WO2003045360A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112870157A (en) * 2019-11-29 2021-06-01 复旦大学附属华山医院 Inflammation-inhibiting gamma aminobutyric acid enema and preparation method and application thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712976A1 (en) * 1997-03-27 1998-10-01 Laves Arzneimittel Use of gamma-aminobutyric acid as cyto-protective agent
DE19712977A1 (en) * 1997-03-27 1998-10-01 Laves Arzneimittel Gmbh Use of gamma-aminobutyric acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19712976A1 (en) * 1997-03-27 1998-10-01 Laves Arzneimittel Use of gamma-aminobutyric acid as cyto-protective agent
DE19712977A1 (en) * 1997-03-27 1998-10-01 Laves Arzneimittel Gmbh Use of gamma-aminobutyric acid

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HARTY RICHARD F ET AL: "Gamma aminobutyric acid protects against acetic acid induced experimental colitis in rats.", GASTROENTEROLOGY, vol. 116, no. 4 PART 2, April 1999 (1999-04-01), Digestive Disease Week and the 100th Annual Meeting of the American Gastroenterological Association;Orlando, Florida, USA; May 16-19, 1999, pages A182, XP009009145, ISSN: 0016-5085 *
SHINTANI NAHOKO ET AL: "Involvement of CD4+ T cells in the development of dextran sulfate sodium-induced experimental colitis and suppressive effect of IgG on their action.", GENERAL PHARMACOLOGY, vol. 31, no. 3, 1998, pages 477 - 481, XP002239562, ISSN: 0306-3623 *

Also Published As

Publication number Publication date
DE10158601A1 (en) 2003-06-12
AU2002350640A1 (en) 2003-06-10
AU2002350640A8 (en) 2003-06-10
WO2003045360A2 (en) 2003-06-05

Similar Documents

Publication Publication Date Title
WO2005058834A3 (en) Quinolines useful in treating cardiovascular disease
WO2003070184A3 (en) Sodium channel blockers
WO2004041203A3 (en) Gemcitabine prodrugs, pharmaceutical compositions and uses thereof
WO2006017384A3 (en) Indazoles useful in treating cardiovascular diseases
AU2003299791A1 (en) Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
WO2003029209A3 (en) Chemical compounds
WO2005046603A3 (en) Pyridine compounds
WO2006017295A3 (en) Tetrapeptide analogs
WO2003033720A8 (en) Protein based tnf-alpha variants for the treatment of tnf-alpha related disorders
WO2006023651A3 (en) Extended treatment of multiple sclerosis
WO2004048551A3 (en) Target for therapy of cognitive impairment
UA85559C2 (en) Aminobenzophenone compounds
WO2003024935A3 (en) Substituted pyrazolyl compounds for the treatment of inflammation
MXPA03011546A (en) New use.
WO2003027075A3 (en) Substituted pyrazolyl benzenesulfamide compounds for the treatment of inflammation
WO2003075953A3 (en) Immunomodulatory polymeric antigens for treating inflammatory pathogies
WO2004087073A3 (en) Treatment of demyelinating conditions
WO2004043379A3 (en) Chemical compounds
WO2004099388A3 (en) Cbl-b polypeptides, complexes and related methods
WO2003072541A3 (en) Chemical compounds
AU2003219981A1 (en) Benzimidazole-derivatives for the treatment of sexual dysfunction
WO2005012275A3 (en) Benzo [1, 2, 5] thiadiazole compounds as cck2 modulators
WO2003045360A3 (en) Use of gaba for the treatment of intestinal inflammations
EP1436279B8 (en) Chemical compounds
WO2004078142A3 (en) Compositions and methods for preventing and treating endotoxin-related diseases and conditions

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP